


Amendments to the Claims:

Please cancel claims 1-72 without disclaimer. Claims 73-86 are newly added and are pending for examination. This listing of claims will replace all prior versions, and listings of claims in the application:


Listing of Claims:

73. (New) A compound having the formula:



wherein:

A-Q is a member selected from the group consisting of:




R^{1a} is a member selected from the group of H, F, Cl and Br;


R^{1e} is a member selected from the group consisting of -H, -F, -Cl, -Br, -OMe, -OH, -Me, -CF₃ and -CH₂NH₂;

R^{1d1}, R^{1d2} and R^{1d4} are each H;

R^{1d3} is selected from the group consisting of:


H, -Me, -F, -Cl, -Br, aryl, heteroaryl, -NH₂, -NMe₂, -NHMe, -NHSO₂NMe, -NHCOMe, -CF₃,
-OH, -OCH₃, -SCH₃, -OCF₃, -OCH₂F, -OCHF₂, -OCH₂CF₃, -OCF₂CF₃, -NO₂, -CN, -CO₂H,
-CO₂Me, -CO₂Et, -CONH₂, -CONHMe, -CONMe₂, -SO₂NH₂, -SO₂CH₃, -SO₂NMe₂, -CH₂OH,
-CH₂NH₂, -CH₂NHMe, -CH₂NMe₂, -OCH₂CO₂H, -OCH₂CO₂Me, -OCH₂CO₂Et, -OCH₂CONH₂,
-OCH₂CONMe₂, -OCH₂CONHMe, -OCH₂CH₂OMe, -OCH₂CH₂OEt, -OCH₂CH₂NH₂,
-OCH₂CH₂NHMe, -OCH₂CH₂NMe₂, -NHCH₂CH₂OMe, -SCH₂CH₂OMe, -SO₂CH₂CH₂OMe,
-OCH₂CH₂SO₂Me, -NHCH₂CH₂NHMe, -NHCH₂CH₂NMe₂, -N(CH₂CH₂OH)₂,
-N(CH₂CH₂OMe)₂, -NHCH₂CO₂H, -NHCH₂CO₂Et, -NHCH₂CONH₂, -NHCH₂CONMe₂,
-NHCH₂CONHMe, -N(CH₃)CH₂CO₂H, -N(CH₃)CH₂CO₂Et, -(NMe)CH₂COOH,
-N(Me)CH₂CONH₂, -N(Me)CH₂CH₂NMe₂, -N(Me)CH₂CH₂OMe, -NHCH₂CH₂OMe,







and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.

74. (New) A compound of claim 73 having a structure selected from the group consisting of:







75. (New) A compound of claim 73 having a structure selected from the group consisting of:



76. (New) A compound of claim 73 having a structure selected from the group consisting of:



77. (New) A compound of claim 73 having the formula:



wherein:


R^{1a} is a member selected from the group of H, F, Cl and Br;

R^{1d1} , R^{1d2} , R^{1d3} and R^{1d4} are each H;

R^{1e} is a member selected from the group of F, Cl, Br, OH, Me and OMe;

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.


78. (New) A compound of claim 77 having a structure selected from the group consisting of:



79. (New) A compound of claim 73:

wherein:

A-Q is a member selected from the group of:




R^{1a} is a member selected from the group of H, F, Cl and Br;

R^{1d1} , R^{1d2} , R^{1d3} , and R^{1d4} are each H;


R^{1e} is a member selected from the group of F, Cl, Br, OH, Me and OMe;

and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.


80. (New) A compound of claim 79, wherein A-Q is:



81. (New) A compound of claim 80 having a structure selected from the group consisting of:



82. (New) A compound of claim 79 having a structure selected from the group consisting of:



83. (New) A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 73.

84. (New) A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound of claim 73.

85. (New) The method of claim 84, wherein the condition is selected from the group consisting of:

acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation, and thrombotic complications associated with the fitting of prosthetic devices.

86. (New) A method for inhibiting the coagulation of a biological sample comprising the step of administering a compound of claim 73.